{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:05Z","timestamp":1707524585355},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"DOI":"10.7759\/cureus.27313","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T21:13:40Z","timestamp":1658870020000},"source":"Crossref","is-referenced-by-count":1,"title":["Suspected COVID-19 Immunization-Induced Probable Catastrophic Antiphospholipid Syndrome"],"prefix":"10.7759","author":[{"given":"Elizabeth A","family":"Seeley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markie","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Berghea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis S","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295-306. 10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00791-7","article-title":"Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: A cohort study in claims databases","volume":"399","author":"Wong HL","year":"2022","unstructured":"Wong HL, Hu M, Zhou CK, et al.. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: A cohort study in claims databases. Lancet. 2022, 399:2191-9. 10.1016\/S0140-6736(22)00791-7","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after COVID-19 vaccination in a large health care organization","volume":"385","author":"Witberg G","year":"2021","unstructured":"Witberg G, Barda N, Hoss S, et al.. Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med. 2021, 385:2132-9. 10.1056\/NEJMoa2110737","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15576","article-title":"Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines","volume":"13","author":"Vidula MK","year":"2021","unstructured":"Vidula MK, Ambrose M, Glassberg H, Chokshi N, Chen T, Ferrari VA, Han Y. Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines. Cureus. 2021, 13:e15576. 10.7759\/cureus.15576","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz T","year":"2019","unstructured":"Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019, 10:941. 10.3389\/fimmu.2019.00941","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0320-8","article-title":"Valvular heart disease in antiphospholipid syndrome","volume":"15","author":"Zuily S","year":"2013","unstructured":"Zuily S, Huttin O, Mohamed S, Marie PY, Selton-Suty C, Wahl D. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep. 2013, 15:320. 10.1007\/s11926-013-0320-8","journal-title":"Curr Rheumatol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(91)90749-Y","article-title":"Cardiac involvement in patients with primary antiphospholipid syndrome","volume":"18","author":"Brenner B","year":"1991","unstructured":"Brenner B, Blumenfeld Z, Markiewicz W, Reisner SA. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol. 1991, 18:931-6. 10.1016\/0735-1097(91)90749-Y","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(97)80034-0","article-title":"Valvular dysfunction in antiphospholipid syndrome: Prevalence, clinical features, and treatment","volume":"27","author":"Nesher G","year":"1997","unstructured":"Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: Prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997, 27:27-35. 10.1016\/S0049-0172(97)80034-0","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.26611","article-title":"State of the art: Evaluation and prognostication of myocarditis using cardiac MRI","volume":"49","author":"Gannon MP","year":"2019","unstructured":"Gannon MP, Schaub E, Grines CL, Saba SG. State of the art: Evaluation and prognostication of myocarditis using cardiac MRI. J Magn Reson Imaging. 2019, 49:e122-31. 10.1002\/jmri.26611","journal-title":"J Magn Reson Imaging"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160493","article-title":"Lupus myocarditis: Initial presentation and longterm outcomes in a multicentric series of 29 patients","volume":"44","author":"Thomas G","year":"2017","unstructured":"Thomas G, Cohen Aubart F, Chiche L, et al.. Lupus myocarditis: Initial presentation and longterm outcomes in a multicentric series of 29 patients. J Rheumatol. 2017, 44:24-32. 10.3899\/jrheum.160493","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317731533","article-title":"Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus","volume":"27","author":"Mavrogeni S","year":"2018","unstructured":"Mavrogeni S, Koutsogeorgopoulou L, Markousis-Mavrogenis G, et al.. Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. Lupus. 2018, 27:564-71. 10.1177\/0961203317731533","journal-title":"Lupus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson RA","year":"2003","unstructured":"Asherson RA, Cervera R, de Groot PG, et al.. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003, 12:530-4. 10.1191\/0961203303lu394oa","journal-title":"Lupus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review","volume":"92","author":"Cervera R","year":"2018","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018, 92:1-11. 10.1016\/j.jaut.2018.05.007","journal-title":"J Autoimmun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.025","article-title":"Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis","volume":"17","author":"Islam MA","year":"2018","unstructured":"Islam MA, Alam F, Cavestro C, Calcii C, Sasongko TH, Levy RA, Gan SH. Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis. Autoimmun Rev. 2018, 17:755-67. 10.1016\/j.autrev.2018.01.025","journal-title":"Autoimmun Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15572","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources","volume":"20","author":"Greinacher A","year":"2022","unstructured":"Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, Warkentin TE. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. J Thromb Haemost. 2022, 20:149-56. 10.1111\/jth.15572","journal-title":"J Thromb Haemost"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23584","article-title":"The of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository","volume":"71","author":"Unlu O","year":"2019","unstructured":"Unlu O, Erkan D, Barbhaiya M, et al.. The of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care Res (Hoboken). 2019, 71:134-41. 10.1002\/acr.23584","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref17","article-title":"Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of serbian patients with primary and secondary antiphospholipid syndrome","volume":"16","author":"Djokovic A","year":"2014","unstructured":"Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J. 2014, 16:162-7.","journal-title":"Isr Med Assoc J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(92)90420-z","article-title":"Cardiac manifestations of the antiphospholipid syndrome","volume":"124","author":"Kaplan SD","year":"1992","unstructured":"Kaplan SD, Chartash EK, Pizzarello RA, Furie RA. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J. 1992, 124:1331-8. 10.1016\/0002-8703(92)90420-z","journal-title":"Am Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6635.1505","article-title":"Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus","volume":"296","author":"Brown JH","year":"1988","unstructured":"Brown JH, Doherty CC, Allen DC, Morton P. Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J (Clin Res Ed). 1988, 296:1505. 10.1136\/bmj.296.6635.1505","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.62.1.61","article-title":"Findings at necropsy in the heart of a patient with anticardiolipin syndrome","volume":"62","author":"Murphy JJ","year":"1989","unstructured":"Murphy JJ, Leach IH. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J. 1989, 62:61-4. 10.1136\/hrt.62.1.61","journal-title":"Br Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2010.03.023","article-title":"Antiphospholipid syndrome and central nervous system","volume":"112","author":"Mayer M","year":"2010","unstructured":"Mayer M, Cerovec M, Rados M, Cikes N. Antiphospholipid syndrome and central nervous system. Clin Neurol Neurosurg. 2010, 112:602-8. 10.1016\/j.clineuro.2010.03.023","journal-title":"Clin Neurol Neurosurg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.03.001","article-title":"Treatment of antiphospholipid syndrome beyond anticoagulation","volume":"206","author":"Dobrowolski C","year":"2019","unstructured":"Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin Immunol. 2019, 206:53-62. 10.1016\/j.clim.2018.03.001","journal-title":"Clin Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu391oa","article-title":"Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report","volume":"12","author":"Lockshin M","year":"2003","unstructured":"Lockshin M, Tenedios F, Petri M, et al.. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003, 12:518-23. 10.1191\/0961203303lu391oa","journal-title":"Lupus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab096","article-title":"Catastrophic antiphospholipid syndrome complicated with essential thrombocythaemia after COVID-19 vaccination: in search of the underlying mechanism","volume":"5","author":"Jinno S","year":"2021","unstructured":"Jinno S, Naka I, Nakazawa T. Catastrophic antiphospholipid syndrome complicated with essential thrombocythaemia after COVID-19 vaccination: in search of the underlying mechanism. Rheumatol Adv Pract. 2021, 5:rkab096. 10.1093\/rap\/rkab096","journal-title":"Rheumatol Adv Pract"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/s3sbgu","article-title":"Catastrophic antiphospholipid syndrome triggered by mRNA COVID-19 vaccine","volume":"40","author":"Moreno-Torres V","year":"2022","unstructured":"Moreno-Torres V, Guti\u00e9rrez \u00c1, Valdenebro M, Ortega A, C\u00edtores MJ, Montero E. Catastrophic antiphospholipid syndrome triggered by mRNA COVID-19 vaccine. Clin Exp Rheumatol. 2022, 40:1054-5. 10.55563\/clinexprheumatol\/s3sbgu","journal-title":"Clin Exp Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/97620-suspected-covid-19-immunization-induced-probable-catastrophic-antiphospholipid-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:14Z","timestamp":1707507374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/97620-suspected-covid-19-immunization-induced-probable-catastrophic-antiphospholipid-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.27313","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,26]]}}}